Supernus, Inc. Common Stock

SUPN

Valor de mercado US$ 6,17 bi

ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.72 per share a year ago.

Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 161 Million in Q3'26 Record Quarterly Adjusted EBITDA of $ 211 Million in Q3'26, Up 76% YoY Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59% , Up 2,100 Basis Points YoY On Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company's website at www.indivior.com.

Indivior Pharmaceuticals is rated a buy, driven by strong SUBLOCADE sales, rising profitability, and an attractive valuation. Q2 2026 saw revenue up 14% and adjusted EBITDA up 111%, with SUBLOCADE revenue growing 21% year-over-year. INDV raised its 2026 guidance, now expecting $1.33B revenue and $720M adjusted EBITDA, with a 54% margin.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether thi.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (such holders, the “Special Dividend Record Holders”) and (ii) $8.13 per share of Indivior common stock underlying Indivior equity awards on the Special Dividend Record Date payable, upon vesting of such equity awards, to the holders of certain Indivior equity awards outstanding as of the Special Dividend Record Date (the “Special Dividend Award Holders”).